

The LoDED study – safe & rapid chest pain management

Submission date 09/04/2018	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 23/04/2018	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 31/08/2023	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

When someone arrives in Accident and Emergency (A&E) with chest pain, it is often hard for doctors to tell if the pain is due to a heart attack. Most patients have to wait in hospital, having two blood tests taken a few hours apart, before a heart attack can be ruled out. Only 1 in 10 of these patients have actually had a heart attack - most have conditions like heartburn that aren't serious. Ruling out heart attacks faster would reassure patients earlier and reduce time spent in hospital. Around 2 million people a year in Britain come to A&E with chest pain. Finding a way for them to be discharged earlier would mean hospitals would be under less pressure. A blood test, called high-sensitivity troponin, may be used to rule out heart attacks using just one blood sample shortly after a patient arrives in A&E. This test measures low levels of heart muscle damage in the blood. The aim of this study is to find out whether this single test works in everyday practice.

Who can participate?

Patients aged 18 and over with chest pain, arriving at one of seven participating A&Es

What does the study involve?

Participants are randomly allocated to one of two groups. One group is discharged after one blood test, if no heart damage is found. The other group have two blood tests as usual. The groups are compared to see how many patients can be discharged within 4 hours, and to see whether the new method saves hospital resources and if patients are reassured when discharged earlier.

What are the possible benefits and risks of participating?

If the participant feels well and they have no further chest pain, they may be discharged after one blood test rather than two and this may allow patients to go home earlier in future. This may be of benefit to the participant. Through previous research, it is known that ruling out heart attacks using a single blood test is likely to be as safe as routine care. Therefore, the risks of missing a heart attack are very low. However, this method is new and still not routine care in most hospitals and the researchers will carefully monitor that it is safe during the study.

Where is the study run from?

1. North Bristol NHS Trust (UK)
2. Royal United Hospitals Bath NHS Foundation Trust (UK)
3. Royal Devon and Exeter NHS Foundation Trust (UK)
4. Plymouth Hospitals NHS Trust (UK)
5. University Hospital of Wales (UK)
6. University Hospitals of Leicester NHS Trust (UK)
7. Royal Berkshire NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

December 2017 to April 2019 (updated 17/06/2019, previously: October 2019)

Who is funding the study?

National Institute for Health Research (NIHR) (UK)

Who is the main contact?

Sarah Campbell

sarah.campbell@plymouth.ac.uk

Contact information

Type(s)

Scientific

Contact name

Ms Sarah Campbell

Contact details

Peninsula Clinical Trials Unit

Room N16

ITTC Building 1

Plymouth Science Park

Davy Road

Plymouth

United Kingdom

PL6 8BX

+44 (0)1752 430 392

sarah.campbell@plymouth.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

37566

Study information

Scientific Title

Randomised controlled trial of the LoDED (Limit of Detection of Troponin and ECG Discharge) strategy versus usual care in adult chest pain patients attending the Emergency Department

Acronym

LoDED

Study objectives

When someone arrives in Accident and Emergency (A&E) with chest pain, it is often hard for doctors to tell if the pain is due to a heart attack. Most patients have to wait in hospital, having two blood tests taken a few hours apart, before a heart attack can be ruled out. Only 1 in 10 of these patients have actually had a heart attack - most have conditions like heartburn that aren't serious. Ruling out heart attacks faster would reassure patients earlier and reduce time spent in hospital. Around 2 million people a year in Britain come to A&E with chest pain. Finding a way for them to be discharged earlier would mean hospitals would be under less pressure. A blood test, called high-sensitivity troponin, may be used to rule-out heart attacks using just one blood sample shortly after a patient arrives in A&E. This test measures low levels of heart muscle damage in the blood. The aim of this study is to find out whether this single test works in everyday practice.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South West – Frenchay Research Ethics Committee, 11/04/2018, ref: 18/SW/0038

Study design

Randomised; Interventional; Design type: Diagnosis, Management of Care

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Chest pain

Interventions

After written consent has been obtained, participants will be randomised to be evaluated using either the existing rule-out strategy used in study centres (control) or the LoDED strategy (intervention) in a 1:1 ratio. The Peninsula Clinical Trials Unit (PenCTU), in conjunction with the study statistician, will provide web-based randomisation, stratified by centre and minimised by age and gender. Appropriate staff at all sites, as delegated by the PI, will be provided with log-in details for the study website.

Control arm

Participant admitted or discharged based on usual rule-out strategy operating in that hospital (varies between recruiting centres). Usual care includes ECG on arrival and usually two hs-troponin tests. All centres take the first sample at presentation, but the minimum time delay between the two samples varies.

Intervention arm

(LoDED Strategy) Participant discharged after a single hs-troponin test at presentation to ED if hs-troponin is below the LoD. Participant not fulfilling discharge criteria will have a second hs-troponin test after 1-6 hours as per usual care.

For all participants, individual trial participation will be from the time of written informed consent until 30 (+5) days after initial ED attendance. The groups will be compared to see how many patients can be discharged within 4 hours, and to see if the new method saves hospital resources and if patients are reassured when discharged earlier.

Intervention Type

Other

Primary outcome measure

Successful early discharge, defined as discharge from hospital within four hours of arrival, without a Major Adverse Cardiac Event (MACE) occurring within 30 days of ED attendance

Secondary outcome measures

1. Length of ED/ED Observation Unit (EDOU) stay, measured in hours. Discharge from the ED within four hours of attendance will be measured using electronic patient tracking systems in use at all study sites, according to the time the patient left the ED (including ED observation units). In the event that a participant is transferred from the ED, to an observation unit or inpatient bed within four hours of attendance and subsequently discharged, length of stay (minutes/hours) will be calculated from electronic patient records and tracking systems
2. Hospital admission and subsequent length of stay - time of admission and discharge to hospital – calculated from electronic patient records and tracking systems
3. Incidence of MACE, within 30 days of the index ED attendance – will be recorded on the SAE form, by the local ED Principal Investigator or designee with reference to relevant clinical information and responses to 30 day follow-up telephone assessments
4. Comparative costs. Resource use data to be collected from all participants with an initial hs-troponin below the LoD, at 30 (+5) days by telephone/by e-mail and electronic patient records (to include GP records where available) will include: use of health services in the last 30 days, length of any subsequent hospital stays (since initial visit to ED); hospital tests carried out during any subsequent hospital admissions, and time off work in the last 30 days. Participants with an initial hs-troponin below the LoD (irrespective of group allocation) will also be asked to complete a second EQ-5D health status questionnaire during their 30-day follow-up
5. Patient satisfaction (quantitative survey) measured using a bespoke written patient

satisfaction questionnaire upon discharge from the ED

6. Acceptability to patients (qualitative methodology): up to 25 participant interviews will be conducted by phone using a topic guide to explore experiences of the participant's stay in ED, any concerns or anxieties they might have

Overall study start date

01/12/2017

Completion date

03/04/2019

Eligibility

Key inclusion criteria

1. Age ≥ 18 years
2. Presenting to ED with chest pain and triggering the chest pain investigation pathway i.e. treating clinician intends to perform investigation to rule out a cardiac cause
3. Peak symptoms occurred < 6 hours prior to presentation to the ED

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned Sample Size: 594; UK Sample Size: 594

Total final enrolment

632

Key exclusion criteria

1. ST-elevation myocardial infarction or ischaemic ECG (new T wave inversion > 3 mm or ST depression > 1 mm) as judged by the treating clinician
2. Clear non-ACS cause for chest pain found at presentation (e.g. pulmonary embolism, pneumonia, aortic dissection)
3. Initial hs-troponin result known to the treating clinician
4. Hospital admission indicated due to other medical/social reasons
5. Chest pain due to arrhythmia (new-onset atrial fibrillation, atrial flutter, sustained supraventricular tachycardia, second-degree or complete heart block, or sustained or recurrent ventricular arrhythmias)
6. Unable to provide written informed consent (lacks capacity)
7. Unwilling to provide written informed consent
8. Pain too severe to provide written informed consent

- 9. Follow-up will be impossible i.e. lives abroad or no fixed abode
- 10. Previous inclusion in the study
- 11. Prisoners
- 12. Pregnancy
- 13. Pre-existing renal failure requiring dialysis

Date of first enrolment

04/06/2018

Date of final enrolment

04/03/2019

Locations

Countries of recruitment

England

United Kingdom

Wales

Study participating centre

North Bristol NHS Trust

Southmead Hospital

Southmead Road

Westbury-On-Trym

Bristol

United Kingdom

BS10 5NB

Study participating centre

Royal United Hospitals Bath NHS Foundation Trust

Combe Park

Bath

United Kingdom

BA1 3NG

Study participating centre

Royal Devon and Exeter NHS Foundation Trust

Royal Devon & Exeter Hospital

Barrack Road

Exeter

United Kingdom

EX2 5DW

Study participating centre
Plymouth Hospitals NHS Trust
Derriford Hospital
Derriford Road
Plymouth
United Kingdom
PL6 8DH

Study participating centre
University Hospital of Wales
Heath Park Way
Cardiff
United Kingdom
CF14 4XW

Study participating centre
University Hospitals of Leicester NHS Trust
Gwendolen House
Gwendolen Road
Leicester
United Kingdom
LE5 4QF

Study participating centre
Royal Berkshire NHS Foundation Trust
Royal Berkshire Hospital
London Road
Reading
United Kingdom
RG1 5AN

Sponsor information

Organisation
North Bristol NHS Trust

Sponsor details
c/o Ms Helen Lewis-White
Floor 3 Learning and Research
Southmead Hospital

Southmead Road
Bristol
England
United Kingdom
BS10 5NB
+44 (0)117 414 9333
helen.lewis-white@nbt.nhs.uk

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/036x6gt55>

Funder(s)

Funder type

Government

Funder Name

NIHR Central Commissioning Facility (CCF); Grant Codes: PB-PG-0416-20012

Results and Publications

Publication and dissemination plan

The protocol is not currently published - a protocol paper will be published as part of the study publication plan. Publication of the LoDED study is planned in a high-impact peer reviewed journal.

Intention to publish date

31/10/2020

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2020	21/05/2020	Yes	No
Protocol article		02/10/2018	17/08/2022	Yes	No

[HRA research
summary](#)

28/06
/2023

No

No

[Results article](#)

Patients' and health professionals'
perceptions

09/12/2020 31/08
/2023

Yes

No